Welireg™ Is Available From Onco360
WELIREG™ (belzutifan) is a hypoxia-inducible factor inhibitor indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.
Dosage and Administration1
The recommended dose for WELIREG is 120 mg (40 mg tablet x 3) orally once daily.
Dosage Forms and Strengths
How to Refer
Oncomed Dba Onco360 or
1WELIREG prescribing information: Merck & Co., Inc. Accessed 7.21. WELIREG © copyright 2021 Merck Sharp & Dohme Corp., a subsidary of Merck & Co., Inc. All rights reserved